# Aspect Biosystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aspect-biosystems

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.aspectbiosystems.com
- Total disclosed funding: $135M
- Latest round: Series B (Jan 8, 2025)
- Investors on record: 8

## About

Aspect Biosystems Ltd., based in Canada, develops innovative bioprinting tissue therapeutics to meet unmet medical needs in regenerative medicine, leveraging advanced technology to create implantable tissues for patients with metabolic and endocrine disorders.Founded in 2013 in Vancouver, Canada, Aspect Biosystems specializes in bioprinting technologies for regenerative medicine. The company has conducted 10 deals and recently raised USD 115.00 mn in Series B funding on January 8, 2025, led by Dimension Management, with other notable participants including Novo Nordisk A/S and Radical Ventures. The founders, Konrad Walus and Tamer Mohamed, have established a strong foundation in bioprinting technology.Aspect Biosystems focuses on developing and commercializing bioprinting tissue therapeutics aimed at addressing unmet medical needs. Their proprietary AI-powered bioprinting platform combines computational tools, therapeutic cells, and biomaterials to create allogeneic tissues, which are utilized for repairing or supplementing biological functions in patients suffering from metabolic and endocrine diseases. The company collaborates with leading pharmaceutical firms to translate these therapies into clinical applications, targeting markets across North America, Europe, and Asia.Aspect Biosystems generates revenue through partnerships and collaborations with pharmaceutical and biotech companies, focusing on the development of bioprinted tissue therapeutics. Their B2B model involves joint development agreements, aligning closely with partners to ensure the advancement of innovative therapies, although specific revenue figures remain undisclosed.With the recent Series B funding of USD 115.00 mn, Aspect Biosystems is poised to enhance its research and development efforts for bioprinted tissue therapeutics. The company plans to expand its product offerings and enter new markets, leveraging this financial support to accelerate its initiatives in regenerative medicine. Specific upcoming products and timelines have not been disclosed, but the funding is aimed at bolstering the company's capabilities in creating advanced therapeutic solutions.

## Funding rounds

- Series B, Jan 8, 2025, $115M — Pangaea Ventures, InBC Investment, Novo Nordisk A/S, Pallasite Ventures, Radical Ventures, Rhino Ventures, JDRF T1D Fund, Dimension Management
- Series A, Jan 9, 2020, $20M — Pangaea Ventures, Pallasite Ventures, Radical Ventures, Rhino Ventures

## Investors

- Pangaea Ventures (https://capitalatlas.ai/funds/pangaea-ventures) — Series A, Series B
- Pallasite Ventures (https://capitalatlas.ai/funds/pallasite-ventures) — Series A, Series B
- Radical Ventures (https://capitalatlas.ai/funds/radical-ventures) — Series A, Series B
- Rhino Ventures (https://capitalatlas.ai/funds/rhino-ventures) — Series A, Series B
- InBC Investment — Series B
- Novo Nordisk A/S — Series B
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series B
- Dimension Management (https://capitalatlas.ai/funds/dimension-management) — Series B